Skip to main content
GALT logo

GALT · Galectin Therapeutics Inc

Track GALT — free
$2.69 -0.12 (-4.27%) At close · Nov 20
Market Cap
$271.35M
Shares
100.88M
Volume · Nov 20 257.85K Avg daily vol (3M) 251.29K

Price & Indicators

 

Key stats

Close
$2.69
Fri 20 Nov
Open
$2.80
Fri 20 Nov
Average volume, 30 days
205K
shares a session
Short interest
9.0M
8.9% of shares · 46.3 days to cover
Day range
$2.67$2.93
Open $2.80 Close $2.69
52-week closing range
$2.08$6.51
Close $2.69 58.7% under the high
Short volume, last session
58%
Last earnings
Aug 14, 2025
Latest filing
10-Q · Nov 16
Price history
Jan 2020 to Nov 2026

Latest documents

2026
Nov 16
Current report 8-K
$105.8 million debt eliminated, cash runway through June 2027

Galectin Therapeutics converted debt from five credit facilities, eliminating $105.8 million of debt, and reported $11.7 million of cash. It believes this funds planned operations through June 2027 and filed belapectin’s registrational Phase 3 protocol with FDA in 3Q 2026.

Financial results
4 source passages
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2026. Elimination of approximately $105.8 million in total debt, consisting of $91.0 million in principal and $14.8 million in accrued interest As of September 30, 2026, the Company had $11.7 million of cash and cash equivalents. Additionally, the Company has $10 million remaining available under a line of credit provided by its Chairman of the Board to fund operations. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through June 2027. Registrational Phase 3 trial protocol submission for belapectin in advanced MASH cirrhosis with portal hypertension was filed with FDA in 3Q 2026. Open the document at this passage
Nov 16
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Belapectin advances toward Phase 3 after FDA agreement

Galectin Therapeutics said FDA agreed on the primary endpoint and regulatory path for potential full approval of belapectin in MASH cirrhosis with portal hypertension; it filed a Phase 3 protocol in the third quarter of 2026 and is seeking partners.

Net loss $3.53M Diluted EPS -$0.04
Read from the MD&A section
3 source passages
The following discussion should be read in conjunction with the accompanying consolidated financial statements and notes thereto of Galectin Therapeutics appearing elsewhere herein. The Company reached agreement with FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin for patients with MASH cirrhosis and portal hypertension. The Company filed a Phase 3 protocol with the FDA in the third quarter of 2026 and is actively exploring strategic and financial partnership opportunities to support the continued development and commercialization of belapectin. Open the document at this passage
Oct 13
Proxy statement DEF 14A Meeting Dec 3, 2026
Proxy statement

Galectin Therapeutics will ask stockholders on December 3, 2026 to elect eleven directors, increase authorized common shares from 150,000,000 to 250,000,000, reserve 3,000,000 additional shares under its 2019 Omnibus Equity Incentive Plan, and ratify Cherry Bekaert LLP as auditor.

Read from the first part of this long document
Oct 13
Annual report to holders ARS
Annual report to holders

Galectin Therapeutics Inc. reported that belapectin 2mg/kg reduced esophageal varices by 49.3% in NAVIGATE’s per-protocol population (p-value<0.05) and by 68.1% among analyzed U.S. patients (p=0.02).

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$23.19M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$11.71M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+39.6%
Year over year · more shares
Price change (1Y)
-53.1%
Trailing year
Short interest
8.9%
Latest settlement · 46.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Neutral Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −16%
below
Price vs 50-day avg −24%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 14%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −16%
trailing
6-month return +11%
trailing
YTD return −35%
this year
Relative strength +20%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +15 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.90% of shares out · ▼ -1.7% MoM · 46.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
108 holders — near 3-yr high, broad support
Squeeze score 72
high risk · 0–100
Fundamentals
Fair
EPS growth +37%
Y/Y
Free cash flow $-23.9M
Quant / Vol
risk profile
Very High
Volatility 91%
annualized · 1-yr
Max drawdown −68%
past year
ATR 10.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Mar 31, 2022
Additional approximately $45-$50 million to cover costs of the N · to reach the planned interim analysis estimated to occur around $45M – $50M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−16% Bearish
Price vs 50-day avg
−24% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
14% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +15 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.90% of shares out · ▼ -1.7% MoM · 46.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
108 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $3 · 14% Range high $7
vs 200-day avg -16% vs 50-day avg -24%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Issuance of shares of common stock to Mr. Uihlein upon conversion 34,376,167 effective July 31, 2026 —
lease cost $18,000 three months ended September 30, 2026 filing —
placebo-adjusted improvement 15.9% at 18 months —
remaining available under a line of credit $10M As of September 30, 2026 —
shares of common stock issued under the 2020 At Market Agreement 118,900 three months ended September 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GALT
Galectin Therapeutics Inc
this stock
$271.35M -35.3% — — 8.9%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
108
% held
15.9%
Net QoQ
+418.0K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
78
View
Short & Settlement
Short Interest Falling
Shares short
9.0M
Days to cover
46.3d
Change
-154.6K sh
View
Short Volume
Short vol %
58%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
5.6K
Value
$19.7K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
54.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-30.8M
EPS diluted
$-0.48
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 16, 2026
This year
19

Galectin Therapeutics said FDA agreed on the primary endpoint and regulatory path for potential full approval of belapectin in MASH cirrhosis with portal hypertension; it filed a Phase 3 protocol in the third quarter of 2026 and is seeking partners.

View
Proposed Sales
Value
$341.4K
Shares
68.3K
Filed
Jun 26, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 14, 2026
View
Investor Relations
Latest news
Galectin Therapeutics Reports Sep…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
GALT -11.8% -15.7% +11.2% -19.0% -35.3%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -3.2% -6.4% +20.3% -10.3% -36.5%
Key facts CIK 1133416 CUSIP 363225202 13F (30d) 104 filings 95 filers Visit website Investor relations